Did you track the mRNA boom beforehand
MRNA’s move higher today isn’t simply a reaction to the news it reflects the market beginning to reprice Moderna’s future. The success of Intismeran is giving investors a glimpse of Moderna’s potential to evolve from a vaccine company into a biotech with the value of a broader cancer-treatment platform$Moderna, Inc.(MRNA)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
